Serving To Educate Primary Care Clinicians On Metabolic Issues
Evidence Based Medicine Header 1
Medical Education Header 2
Peer-to-peer Exchange Header 3
Metabolic Diseases Header 4
News: Prescriber's Letter July 2015
DIABETES MEDICATION SAFETY
new warnings about a possible increased risk of heart failure with saxagliptin (Onglyza, etc) and alogliptin (Nesina, etc)
whether Invokana (canagliflozin) and other SGLT2 inhibitors or "flozins" are linked to ketoacidosis

 

For the most recent full article AND to access all of the benefits of Prescriber's Letter subscribe to an option below:

Prescriber's Letter offers PCMG Members a 10% discount at two subscription levels:

The Gold Subscription is $129 and includes CME

The Platinum Subscription is $189 and provides enhanced CME and Live Webinar access 

Enter Discount Code PCMG15 when ordering either subscription HERE